Capitello 291 News Today

Fast, Ad-Free News Updates

Stay updated with breaking news from Capitello 291. Real-time updates on events, politics, business and more.

Capivasertib and Fulvestrant for Patients with Aromatase Inhibitor-resistant Hormone Receptor-positive/Human Epidermal Growth Factor Receptor 2-negative Advanced Breast Cancer: Results from the Phase III CAPItello-291 Trial

November 28, 2023

Hope Rugo, MD reviews key data from the CAPItello-291 phase 3 trial recently presented at the San Antonio Breast Cancer Symposium in December 2022.

Aromatase Inhibitor Resistant Hormone Human Epidermal Growth Factor Receptor Advanced Breast Cancer Breast Cancer Hr Breast Cancer Her2 Breast Cancer

Source: onclive.com

HR+/HER2- Breast Cancer: Inhibiting the PI3K/AKT/mTOR Pathway

August 8, 2023

Dr Vidal expands on use of PI3K/AKT/mTOR pathway inhibitors following frontline progression, focusing on the PI3K inhibitor alpelisib for patients with PIK3CA mutations, as well as capivasertib, an AKT inhibitor in development.

Aditya Bardia Gregory Vidal Komal Jhaveri Hr Her2 Breast Cancer Cdk4 6 Inhibitors Second Line Therapies

Source: onclive.com

Explore More Categories

World News India News Business Technology Sports Entertainment Health Science

Navigation

Capitello 291 News Today

Capivasertib and Fulvestrant for Patients with Aromatase Inhibitor-resistant Hormone Receptor-positive/Human Epidermal Growth Factor Receptor 2-negative Advanced Breast Cancer: Results from the Phase III CAPItello-291 Trial

HR+/HER2- Breast Cancer: Inhibiting the PI3K/AKT/mTOR Pathway

Explore More Categories